Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.
Hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reaction to a combination product of trimethoprim and sulfamethoxazole were desensitized orally. Six of the seven patients included in the study successfully completed the desensitization protocol and received trimethoprim-sulfamethoxazole for 5 to 7 months after desensitization (mean length of treatment, 5.7 months) for prophylaxis of Pneumocystis carinii pneumonia. The small number of patients and the short follow-up allow us to suggest that oral desensitization may be an effective and inexpensive means to treat hemophiliacs infected with human immunodeficiency virus with trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis carinii pneumonia.
Department of Pediatrics, University of Arkansas for Medical Science, Little Rock.
M
M
Kletzel
S
S
Beck
J
J
Elser
N
N
Shock
W
W
Burks
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
D015662:Trimethoprim, Sulfamethoxazole Drug Combination